EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

aXichem AB (AXIC-A) fair value: what the stock is really worth

We calculate from audited financials what aXichem AB is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Basic Materials · SE · ISIN SE0005250719

AA Thin data Sep 13, 2026

aXichem AB

AXIC-A · ST

Weakest SetupStrongly overvalued and low quality.

!Fair value kr 0.8245 · Strongly overvalued (−55%)
!Quality 28/100
!Mixed Growth (revenue 5y +72.0 %/yr)
!Loss-making · -77.5% net margin (TTM)
!negative free cash flow
!Trails peers (3/9)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch aXichem AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 31.14 kr 1.06 Fair Value kr 0.8245 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range kr 1.06 – kr 31.14 · fair‑value band kr 0.5780 – kr 1.07 · the kr 1.83 price screens above the kr 0.8245 fair value. Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden.

Show more

aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. The company offers aXivite, a natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen-feed, a solution for enhanced health for chickens, hens, pigs, and piglets. The company was founded in 1999 and is based in Malmö, Sweden.

Stock analysis

aXichem AB (AXIC-A) currently trades at kr 1.83, while our model-based Fair Value estimate is kr 0.8245, implying the stock looks roughly 121.3% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: kr 0.5780 (bear) to kr 1.07 (bull), the price of kr 1.83 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Basic Materials sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

aXichem AB reported revenue of 18.4M SEK in FY2025 versus 4.4M SEK in FY2021, a compound +43.4%/yr. Reported net income was −17.6M SEK in FY2025.

Key figures

Market cap 162M SEK (≈ $16.7M) · P/S ratio 4.91 · EPS (TTM) kr −0.2500 · Net margin −95.6% · Return on equity −23.7% · Return on assets (EBIT) −25.3% · Operating margin −73.9% · Revenue (TTM) 18.9M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 55% below its 52-week high and 61% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −47% fair-value upside, at −55%, AXIC-A screens richer than that median.

Fair Value models

Bear kr 0.5780 Fair Value kr 0.8245 Bull kr 1.07
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 0.3900 kr 0.5200 kr 0.7800 51
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.3900 kr 0.5200 kr 0.7800 51

Open the full fair value analysis →

Notify me when AXIC-A reaches fair value

Put AXIC-A on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 28/100

Of which business quality 31 · Market factors (momentum, volatility) 49

Profitability 3
Margins and returns on capital today
Quality Growth 60
Are margins and returns improving?
Cashflow 3
Earnings quality: real cash, not paper profit
Fin. Strength 78
Balance sheet, leverage, solvency risk
Investment 51
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 71
Price trend over the last 3–12 months (market factor)
52W Momentum 12
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+115.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+54.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.0%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,101.3% (2020) → −91.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

AXIC-A screens 121% overvalued. Compare with Linde plc →

Compare aXichem AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 706 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Profitability
Return on assets −13% · Bottom 25%
Net margin (TTM) −78% · Bottom 25%
Operating margin (TTM) −74% · Bottom 25%
Growth and dividend
Revenue growth 13% · Above median

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/B 0.32× · Cheapest 25%
P/S (TTM) 0.90× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)65 · sector 21
PAST (return on equity)0 · sector 23
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)0 · sector 29

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Linde plc LIN $466.22 $425.24 −9%
The Sherwin-Williams Company SHW $323.31 $143.38 −56%
Ecolab Inc ECL $276.18 $96.18 −65%
Air Products and Chemicals, Inc APD $291.43 $122.14 −58%
Nan Ya Plastics Corporation 1303 234.50 TWD 306.47 TWD +31%
Givaudan SA GIVN CHF 3,164 CHF 1,523 −52%
Wanhua Chemical Group 600309 ¥74.50 ¥68.03 −9%
500820 500820 ₹2,470 ₹393.15 −84%
Sika AG SIKA CHF 185.00 CHF 98.89 −47%
Novozymes A/S NSISB kr 427.30 kr 383.60 −10%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

aXichem AB · Fair Value
kr 0.8245 −121%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "aXichem AB Fair Value". https://www.fairvalue-calculator.com/stock/AXIC-A

Frequently asked questions

Is aXichem AB (AXIC-A) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of kr 0.8245 versus a price of kr 1.83, about −55% upside (overvalued).
What is the fair value of AXIC-A?
Our model-based fair value for aXichem AB is kr 0.8245 (as of Sep 13, 2026), built from audited fundamentals. The current price: kr 1.83.
What is the quality score of AXIC-A?
aXichem AB has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for aXichem AB (AXIC-A)?
Our model-based price target is the fair value of kr 0.8245 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario kr 0.5780, optimistic scenario kr 1.07. It is a calculation from audited fundamentals, not an analyst target.
What is the aXichem AB stock forecast for 2026?
Our models put fair value at kr 0.8245, about −55% upside versus a price of kr 1.83 (overvalued). Cautious scenario kr 0.5780, optimistic scenario kr 1.07. The calculation is refreshed regularly with new filings.
What is the revenue of aXichem AB (AXIC-A)?
aXichem AB reported trailing-twelve-month revenue of about 18.9M SEK (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of aXichem AB (AXIC-A)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For aXichem AB it is kr 0.8245 per share (as of Sep 13, 2026), against a price of kr 1.83. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is aXichem AB stock overvalued or undervalued in 2026?
As of Sep 13, 2026, AXIC-A trades above its calculated fair value: price kr 1.83, fair value kr 0.8245, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AXIC-A?
No. The price is what the market pays today (kr 1.83); the fair value is what the company's own numbers justify (kr 0.8245). For aXichem AB the two are kr 1.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is aXichem AB worth?
The market values aXichem AB at about 162M SEK (market capitalisation, as of Sep 13, 2026). Per share that is kr 1.83; our models calculate a fair value of kr 0.8245 per share.
What do the bullish and bearish scenarios say about AXIC-A?
Our models span a range for aXichem AB: cautious scenario kr 0.5780, base kr 0.8245, optimistic kr 1.07 per share (as of Sep 13, 2026, price kr 1.83). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of aXichem AB (AXIC-A)?
Balance-sheet figures for aXichem AB (as of Sep 13, 2026): return on equity −23.7%. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is AXIC-A from its 52-week high?
aXichem AB trades at kr 1.83, about 55% below its 52-week high of kr 4.10 and 61% above the low of kr 1.14 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.8245 is for.
Which stocks are comparable to aXichem AB?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is aXichem AB stock attractive at the current price?
The data as of Sep 13, 2026: price kr 1.83, calculated fair value kr 0.8245 (−55%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AXIC-A calculated?
We run aXichem AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.8245, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. aXichem AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with aXichem AB right now?
The price sits above even our optimistic bull case (kr 1.07). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.5780 to kr 1.07) leaves room in how you read the outcome.

Key figures of aXichem AB

How large is the market capitalisation of aXichem AB (AXIC-A)?
The market capitalisation of aXichem AB is 162M SEK (≈ $16.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of aXichem AB (AXIC-A)?
The price-to-sales ratio of aXichem AB is 4.91 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of aXichem AB (AXIC-A)?
Earnings per share at aXichem AB are kr −0.2500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of aXichem AB (AXIC-A)?
The net margin of aXichem AB is −95.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of aXichem AB (AXIC-A)?
The return on equity (ROE) of aXichem AB is −23.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of aXichem AB (AXIC-A)?
On an EBIT basis the return on assets of aXichem AB is −25.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of aXichem AB (AXIC-A)?
The operating margin of aXichem AB is −73.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at aXichem AB (AXIC-A)?
Revenue at aXichem AB is growing +13.0% versus a year earlier (3y avg +54.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does aXichem AB (AXIC-A) generate?
The free cash flow of aXichem AB is −16.0M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does aXichem AB (AXIC-A) carry?
The net debt of aXichem AB is 1.6M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch aXichem AB in the live analysis

One click puts aXichem AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.